Payment overview · 2025
General Payments
$1,723.59
64 reported records · 16 companies
Healthcare provider profile · identity verified
Munib Shabbir Daudjee, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HOUSTON, TX · NPI 1417141706
Verified facts
What the public records show
CMS Open Payments records show Munib Shabbir Daudjee, M.D. received $1,723.59 in general payments during 2025 across 64 reported records.
ABBVIE INC. accounted for 20.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Rybelsus, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $348.84 | 20.2% | 27 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $255.31 | 14.8% | 9 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $168.44 | 9.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $162.52 | 9.4% | 6 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $160.93 | 9.3% | 8 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $137.66 | 8.0% | 2 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $136.03 | 7.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $110.75 | 6.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $87.37 | 5.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $52.66 | 3.1% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.06 | 1.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $20.06 | 1.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.26 | 1.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.36 | 0.9% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.77 | 0.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $13.57 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,716.07 | 63 |
| Education | $7.52 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $217.50 | 7 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $168.44 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $165.61 | 12 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $156.08 | 5 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $153.41 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $145.05 | 13 | 2025 |
Source payment records
|
|||||
| General - Vascular Intervention Normalized: general vascular intervention |
Device | Boston Scientific Corporation | $137.66 | 2 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $136.03 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $110.75 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $87.37 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $74.47 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $60.92 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $52.66 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $37.81 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $34.24 | 4 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $29.65 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $20.06 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.26 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.36 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.77 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.57 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $6.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 30 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 133 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
30 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
79 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
133 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 462 | 164 |
| Losartan Potassium | Losartan Potassium | 363 | 119 |
| Prednisone | Prednisone | 344 | 196 |
| Amlodipine Besylate | Amlodipine Besylate | 272 | 98 |
| Levothyroxine Sodium | Levothyroxine Sodium | 258 | 73 |
| Pantoprazole Sodium | Pantoprazole Sodium | 242 | 109 |
| Metformin Hcl | Metformin Hcl | 221 | 72 |
| Meloxicam | Meloxicam | 194 | 83 |
| Azithromycin | Azithromycin | 168 | 119 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 139 | 47 |
| Ozempic | Semaglutide | 133 | 27 |
| Ezetimibe | Ezetimibe | 116 | 45 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 115 | 81 |
| Atenolol | Atenolol | 113 | 35 |
| Gabapentin | Gabapentin | 110 | 49 |
| Glimepiride | Glimepiride | 109 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 109 | 40 |
| Lisinopril | Lisinopril | 109 | 38 |
| Carvedilol | Carvedilol | 107 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 105 | 40 |
| Furosemide | Furosemide | 104 | 46 |
| Trazodone Hcl | Trazodone Hcl | 102 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 97 | 39 |
| Omeprazole | Omeprazole | 93 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 90 | 48 |
| Cephalexin | Cephalexin | 85 | 68 |
| Metformin Hcl Er | Metformin Hcl | 84 | 33 |
| Doxycycline Hyclate | Doxycycline Hyclate | 81 | 53 |
| Jardiance | Empagliflozin | 79 | 25 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 77 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 35 |
| Alendronate Sodium | Alendronate Sodium | 72 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 71 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 26 |
| Tramadol Hcl | Tramadol Hcl | 68 | 34 |
| Alprazolam | Alprazolam | 65 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 64 | 22 |
| Pregabalin | Pregabalin | 63 | 12 |
| Montelukast Sodium | Montelukast Sodium | 58 | 23 |
| Clonidine Hcl | Clonidine Hcl | 55 | 26 |
| Doxazosin Mesylate | Doxazosin Mesylate | 54 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 28 |
| Pioglitazone Hcl | Pioglitazone Hcl | 52 | 20 |
| Meclizine Hcl | Meclizine Hcl | 51 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 19 |
| Finasteride | Finasteride | 49 | 21 |
| Mupirocin | Mupirocin | 47 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 46 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | suppressed |
| Famotidine | Famotidine | 44 | 19 |
| Potassium Chloride | Potassium Chloride | 44 | 29 |
| Cefdinir | Cefdinir | 43 | 33 |
| Januvia | Sitagliptin Phosphate | 43 | 14 |
| Methocarbamol | Methocarbamol | 43 | 25 |
| Ondansetron Odt | Ondansetron | 41 | 31 |
| Repatha Sureclick | Evolocumab | 40 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | 18 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 37 | 22 |
| Hydrocortisone | Hydrocortisone | 35 | 24 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 34 | suppressed |
| Allopurinol | Allopurinol | 33 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 33 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | 16 |
| Farxiga | Dapagliflozin Propanediol | 30 | 14 |
| Valacyclovir | Valacyclovir Hcl | 30 | 16 |
| Fluconazole | Fluconazole | 29 | 17 |
| Valsartan | Valsartan | 29 | 13 |
| Ketoconazole | Ketoconazole | 28 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 27 | 22 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 26 | 13 |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 24 | 17 |
| Celecoxib | Celecoxib | 24 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Simvastatin | Simvastatin | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Nystatin | Nystatin | 22 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Repaglinide | Repaglinide | 22 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 13 |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Brilinta | Ticagrelor | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 18 | suppressed |
| Eliquis | Apixaban | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 16 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Pulmicort Flexhaler | Budesonide | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Letrozole | Letrozole | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,723.59 · 64 records | ABBVIE INC. | Dexcom G6 Transmitter, FARXIGA, General - Vascular Intervention, KRYSTEXXA, Kerendia, OTEZLA, Ozempic, QULIPTA, Qelbree, REPATHA, REZDIFFRA, Rybelsus, SYNTHROID, Symbravo, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZORYVE | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error